At baseline, 2735 of the patients (83.0%) had established cardiovascular disease, chronic kidney disease, or both
This system-level approach enables combinatorial and rational drug designing and characterization of new master regulators for precision medicine
A one-size-fits-all approach doesnt work when it comes to weight loss assisted by GLP-1 drugs
GLP-1 Receptor Activation Modulates Appetite- and Reward-related Brain Areas in Humans Diabetes 63(12) 2014PMID: 24953787 PubMed 6 Rubino D, Abrahamsson N, Davies M, et al
doi: 10.1093/advances/nmaa139
At 52 weeks, the eGFR decline was 1.1 in the dulaglutide (1.5 mg) group, 1.5 in the dulaglutide (0.75 mg) group, and 2.9 in the glargine group